Perseguendo la Visione di un Mondo Libero dal Dolore https://lnkd.in/dvxHGF9g #WeAreGrünenthal #worldfreeofpain #clinicaltrial #innovazione #ricerca
We enrolled the first participants in a first-in-human trial with one of our proprietary nociceptin (NOP) receptor agonists. Building on many years of pioneering research, we aim to deliver a unique and transformative first-in-class treatment option to millions of chronic pain patients. With our candidate, which shows best-in-class selectivity, we aim to solely target the NOP receptor. This may provide robust pain relief in a broad range of chronic pain indications without the serious central nervous system-related side effects associated with opioids. Read the full Press Release through the link in the comments. #WeAreGrünenthal #worldfreeofpain #clinicaltrial